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Abstract. ~2 integrin (CDlla,b,c/CD18)-mediated c ll
adhesion is required for many leukocyte functions. 
Under normal circumstances, the integrins are 
nonadhesive, and become adhesive for their cell sur- 
face ligands, the intercellular adhesion molecules 
(ICAMs), or soluble ligands such as fibrinogen and 
iC3b, when leukocytes are activated. Recently, we 
defined a peptide derived from ICAM-2, which 
specifically binds to purified CDlla/CD18. Further- 
more, this peptide strongly induces T cell aggregation 
mainly mediated by CDlla/CD18-ICAM-1 interaction, 
and natural killer cell cytotoxicity. In the present 
study, we show that the same ICAM-2 peptide also 
avidly binds to purified CDllb/CD18, but not to 
CDllc/CD18. This binding can be blocked by the 
CD1 lb antibody OKM10. The peptide strongly stimu- 
lates CDllb/CD18-ICAM-l-mediated cell aggregations 
of the monocytic ell lines THP-1 and U937. The ag- 
gregations are energy and divalent cation-dependent. 
The ICAM-2 peptide also induces CDllb/CD18 and 
CDllc/CD18-mediated binding of THP-1 cells to 
fibrinogen and iC3b coated on plastic. These findings 
indicate that in addition to induction of CDlla/CD18- 
mediated cell adhesion, the ICAM-2 peptide may also 
serve as a "trigger" for high avidity ligand binding of 
other ~2 integrins. 
T 
HE leukocyte-specific ~2 integrins (CDll/CD18), ~ 
consist of three high mol wt heterodimers with spe- 
cific ot chains (CDlla,b,c) and a common /3 chain 
(CD18), and play a prominent role in mediating diverse cell 
adhesions required for many leukocyte functions (Springer, 
1990; Arnaout, 1990; Patarroyo et al., 1990). 
CDlla/CD18 lymphocyte function-associated antigen-1 
(LFA-1), which is mainly found on mononuclear leukocytes, 
probably binds to the NH2-terminal immunoglobulin do- 
mains of the intercellular adhesion molecules (ICAM)-I 
(CD54) (Rothlein et al., 1986; Patarroyo et al., 1987; Staun- 
ton et al., 1990; Berendt et al., 1992), ICAM-2 (CD102) 
(Staunton et al., 1989; Nortamo et al., 1991b; de Fougerolles 
et al., 1991), and ICAM-3 (CD50) (de Fougerolles et al., 
1992; Vazeux et al., 1992; Fawcett et al., 1992; Juan et al., 
1993), members of the immunoglobulin superfamily. CD1 lb/ 
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1. Abbreviations used in this paper: BSA, bovine serum albumin; 
CDI1/CDI8, leukocyte-specific ~2integrins; CDlla/CD18 (LFA-1), lym- 
phocyte function-association antigen-l; ICAM, intercellular dhesion mol- 
ecule. 
CD18 (Mac-l), which is expressed primarily on cells of the 
myelo-monocytic lineage, binds to ICAM-1 through the third 
immunoglobulin domain (Diamond et al., 1991). In addi- 
tion, CDllb/CD18 also binds to several soluble ligands in- 
cluding the complement fragment iC3b (Belier et al., 1982; 
Wright et al., 1983), fibrinogen (Wright et al., 1988; Altieri 
et al., 1988), and factor X (Altieri and Edgington, 1988a), 
which become insolubilized uring activation of the comple- 
ment and clotting cascades. CDllc/CD18 (p150,95) is en- 
riched on macrophages. The ligands for CDllc/CD18 are 
poorly characterized. It has been shown that CDllc/CD18 
binds to iC3b (Micklem and Sim, 1985; Myones et al., 
1988), and recent reports uggest that it also binds to fibrino- 
gen (Loike et al., 1991; Postigo et al., 1991), and at least o 
one counter-receptor n the surface of endothelial cells 
(Stacker and Springer, 1991). 
The leukocyte integrins need to be activated inorder to be- 
come adhesive. The molecular mechanisms involved in the 
activation of CDll/CD18 are incompletely understood. 
Quantitative as well as qualitative changes occur in these re- 
ceptors after cell activation. Phorbol ester treatment (Patar- 
royo et al., 1985; Rothlein and Springer, 1986), or cross- 
linking the T cell receptor on lymphocytes (Dustin and 
Springer, 1989) induces a high avidity state of CD1 la/CD18 
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for ICAM-1, without any substantial increase in lymphocyte 
surface xpression of this integrin. CD1 la/CD18 can also be 
activated by monoclonal ntibodies reacting with a variety of 
leukocyte cell surface glycoproteins (van Kooyk et al., 1989; 
Koopman et al., 1990; Kansas and Tedder, 1991), evidently 
through "inside-out" signaling. In addition, certain mono- 
clonal antibodies against he ct chain of CDlla/CD18 has 
been shown to be able to induce CDlla/CD18-dependent 
homotypic T cell adhesion (Koopman et al., 1992; Landis 
et al., 1993), indicating that integrin activation could also be 
induced by direct ligand binding from the outside of the cells. 
Unlike CDlla/CD18, the amount of cell surface CDllb/ 
CD18 and CD1 lc/CD18 on granulocytes and monocytes can 
be rapidly upregulated by translocation f these two recep- 
tors from an intracellular pool to the cell surface in response 
to cell activation (Miller et al., 1987; Bainton et al., 1987). 
However, the change in CD1 lb/CD18 surface xpression that 
occurs after stimulation does not parallel the kinetics or 
magnitude of cell adhesion (Buyon et al., 1988; Lo et al., 
1989). Thus, CD1 lb/CD18 is hypothesized to undergo addi- 
tional qualitative conformational changes that facilitate ad- 
hesion (Buyon et al., 1988; Lo et al., 1989; Philips et al., 
1988; Vedder and Harlan, 1988). The phorbol ester and 
adenine nucleotide ADP-induced functional modulation of 
CDllb/CD18 appears to involve allosteric or qualitative re- 
modeling of the receptor characterized bythe formation of 
activation-dependent neoantigenic epitopes (Diamond and 
Springer, 1993; Altieri and Edgington, 1988b). Alterna- 
tively, the enhanced avidity of CDllb/CD18 could be due to 
a signal to cluster the receptors in the plane of the membrane 
(Detmers et al., 1987). 
Recent work has demonstrated that ICAM-1, ICAM-2, and 
ICAM-3 provide important costimulatory signals via their 
adhesive interactions with the CD11a/CD18 complex during 
the CD3/TCR-mediated activation of resting T cells (van Se- 
venter et al., 1990; Damle et al., 1992; Hern/~ndez-Caselles 
et al., 1993). Furthermore, ICAM-1 has been shown to be 
able to induce the high affinity state of CD1 la/CD18 charac- 
terized by expression of the m_Ab 24 epitope (Cabanas and 
Hogg, 1993), which has been thought to be a "reporter" of 
the activated state of CDlla/CD18 (Dransfield et al., 1990). 
However, there is no direct evidence for inducing ahigh avid- 
ity state of leukocyte integrins by direct ligand binding. 
ICAM-2 is the second ligand found for CDlla/CD18 
(Staunton et al., 1989). The external portion of this mole- 
cule consists of two immunoglobulin domains, which have 
34% identity in amino acid sequences with the two NH2- 
terminal domains of ICAM-1 and ICAM-3. To identify the 
binding site(s) in ICAM-2 for CDlla/CD18, we recently syn- 
thesized several peptides from the first immunoglobulin do- 
main of ICAM-2, and characterized a 22-amino acid long 
peptide, PI, which specifically binds to CDlla/CD18 (Li et 
al., 1993b). Furthermore, the peptide strongly stimulates 
blood T cell aggregation mainly mediated by CD1 ladCD18- 
ICAM-1 interaction, and natural killer cell cytotoxicity (Li 
et al., 1993a). In the present study, we report hat he ICAM-2 
peptide also binds to purified CD1 lb/CD18, but not to CDllc/ 
CD18. The peptide strongly induces CD1 lb/CD18-ICAM-1- 
mediated homotypic ell adhesion of monocytic ell lines, 
and CDllb/CD18 and CDllc/CD18-mediated binding of 
leukocytes to fibrinogen and iC3b. 
Materials and Methods 
Cell Culture 
The endothelial cell line Eahy926 was cultured in DMEM (Sigma Chem. 
Co., St. Louis, MO) containing hypoxanthine/aminopterirdthymidine, and 
10% of FCS (Flow Laboratories, Irvine, Scotland). Eahy926 cells were 
stimulated by incubating them with 10 ng/ml of TNF-tx (Boehringer Mann- 
heim, Mannheim, Germany) overnight (Nortamo et al., 1991a). The mono- 
cytic cell line THP-1 (American Type Culture Collection, Rockville, MD) 
(Tsuchiya et al., 1980) was maintained incontinuous culture in RPMI 1640 
medium (GIBCO BRL, Gaithersburg, MD) containing 10% FCS, 2 mM 
L-glutamine (Biological Industries, Kibbutz Bet Haemek, Israel), 10 mM 
Hepes, and 50 ~tM 2-mercaptoethanol (Fluka Chemie AG, Switzerland). 
The monocytic ell line U937 (Sundstr6m and Nilsson, 1976) was cultured 
in RPMI !640 supplemented with 10% FCS, 100 u/ml of penicillin, 100 
~g/ml of streptomycin a d 2 mM of L-glntamine. 
Peptide Synthesis 
Peptides were synthesized on a model 430A peptide synthesizer, using 
Fmoc-chemistry (Applied Biosystems, Inc., Foster City, CA). The struc- 
tures were confirmed by FAB-mass pectrometric analysis (JEOL SX-102). 
The sequence of the ICAM-2 peptide P1 is GSLEVNCSTTCNQPEVG- 
GLETS. The amino acids of the control peptide P8 are the same as those 
of P1, but in random order, except that the two conserved cysteine residues 
are in the right positions (Li et al., 1993b). After synthesis, the PI and P8 
peptides were reduced with dithiothreitol (1:1.5 by wt/wt, in 0.1 M 
NaHCO3, pH 8.0) for 1.5 h at room temperature, and purified by high pres- 
sure liquid chromatography, using a reverse phase column (Waters Cis). A 
COOH-terminal tyrosine was added to the peptides to enable t25I-labeling 
(Li et al., 1993b). 
Monoclonal Antibodies 
A panel of monoclonal ntibodies that bind to immunocbemically and func- 
tionally distinct epitopes on the leukocyte integrins CDlla,b,c/CD18 was 
used. The monoclonal ntibody 7FA (Nortamo et al., 1988) reacts with the 
common ~/ chain of the three leukocyte integrins. Antibody TSl/22 
(S/mcbez-Madrid etal., 1982) recognizes an epitope on the c~ subunit of 
CDlla/CD18. Monoclonal antibodies OKM1, OKM10 (Wright et al., 
1983), LM2/1 (Miller et al., 1986), and 60.1 (Wallis et al., 1986) are 
specific for spatially separate pitopes localized on the ~ chain of 
CDllb/CD18. Antibodies 3.9 (Myones et al., 1988) and 2El (from the 5th 
International Workshop on Human Leukocyte Differentiation Antigens) re- 
act with different epitopes on the cc subunit of CDIIc/CDIS. Antibody 
LM609 recognizes an epitope on the c~ chain of the vitronectin receptor 
(c¢v~3) and the recognition requires association of the c~ and ~ subunits 
(Cheresh and Spiro, 1987). The ICAM antibodies were LB-2 (ICAM-I) 
(Clark et al., 1986), B-T1 (ICAM-2) (Diacione, Besancon Cedex, France) 
and CGI06 (ICAM-3) (Cordell et al., 1994). A mouse IgG1 negative control 
was from Dakopatts A/S, Denmark. 
Chemicals 
ADP, 2-deoxy-D-glucose (DG) and cytochalasin B used were from Sigma 
Chem. Co., dibutyryl cAMP from Boehringer GmbH. 
Purification of the Complement Fragment iC3b 
The complement protein C3 was isolated from human plasma s described 
(Koistinen et al., 1989), dissolved in 0.01 M Na-5,5'-diethylbarbiturate, 
0.15 M NaCI, 0.02% NAN3, pH 7.3, and converted to C3b by incubating 
with 0.5% (wt/wt) trypsin (Sigma) for 5 min at room temperature, followed 
by addition of 1.5% (wt/wt) soybean trypsin inhibitor. C3b was converted 
to iC3b by incubating with 0.15 mg/ml factor H and 0.012 mg/ml factor I
for 1 h at 37°C. iC3b was isolated from the mixture on a Mono Q column 
by eluting with a 0.05-0.4 M NaCI gradient in 0.01 M phosphate, 5 mM 
EDTA, pH 7.5. 
Binding of I:5I-labeled P1 Peptide to Purified 
CD11b/CD18 and CDllc/CD18 
CDllb/CD18 and CDllc/CD18 were purified from human buffy coat cell 
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lysates by affinity chromatography on monoclonal ntibody LM2/1-Sepha- 
rose CL 4B and 3.9-Sepharose CL 4B, respectively, and eluted at pH 11.5 
in the presence of 2 mM MgCI2 and 1% n-octyl glucoside (Dustin and 
Springer, 1989). The purity of the proteins were checked by polyacrylamide 
gel electropboresis (PAGE) in the presence of SDS (Laemmli, 1970). The 
heterodimeric forms of the purified integrins were examined by running 
the preparations once again through the same affinity columns and checking 
the eluates by SDS-PAGE. The proteins were diluted 1:10 with 25 mM Tris, 
pH 8.0, 150 mM NaCI and 2 mM MgCI2, and attached to flat-bottomed, 
96-well mierotiter plates (Dynatech Laboratories, VA) by overnight incuba- 
tion at 4°C. The wells were blocked with 1% BSA for 1 h at room tempera- 
ture. 12 pmol of 125I-labeled P1, labeled by using the chloramine-T method 
(Greenwood et al., 1963), was added to each well in 40 td of 0.15 M NaC1, 
0.01 M sodium phosphate, pH 7.4 (PBS), containing 2 mM MgCI2, 0.5% 
BSA and 0.02 % NaN3 with or without nonradioactive p ptides, monoclo- 
nal antibodies, or some soluble ligands for CD1 lb/CDI 8, and incubated for 
1 h at 37°C. After washing the wells for three times with the binding buffer, 
the attached ~25I-labeled PI was solubilized with 1% SDS and counted. 
Saturation binding of peptide P1 to purified CD1 lb/CD18 was analyzed in 
dose response xperiments in which increasing amounts of nonradioactive 
P1 were incubated in CDllb/CDl8-coated wells together with 12 pmol of 
125I-labeled P1. Nonspecific binding was defined as the amount of 125I-P1 
bound to CDI Ib/CD18 in the presence of a 100-fold excess of unlabeled PI, 
and was substracted from the total to calculate specific binding. 
Binding of Endothelial Cells to Purified CDllc/CD18 
Purified CD1 lc/CDI8 was diluted 1:10 and coated on flat-bottomed, 96-well 
microtiter plates, and the plates were saturated with 1% BSA as described 
above. The control plates were treated with BSA only. TNF-t~-stimulated 
Eahy926 cells were removed from the tissue culture flasks with 5 mM EDTA 
in PBS, washed, and resuspended in DMEM, 40 mM Hepes, pH 7.2, 2 mM 
MgCI2 and 5% FCS. Cells (5 × 104) in 50/~1 were added to each well in 
the absence or presence of 50/~g/ml of mAb 3.9 or control antibody MIgG, 
and incubated for 1 h at 37°C. Unbound cells were removed by gentle wash- 
ing. The binding was quantitated by counting bound cells using 200× 
magnification of four randomly chosen fields from each well. 
Aggregation Assays 
Cells were washed with RPMI 1640 medium containing 40 mM Hepes, 2 
mM MgCI2 and 2 mM CaCI2 and resuspended to a concentration f 106 
cells/ml. Aliquots of 100 #l were added to each well of flat-bottomed, 96- 
well microtiter plates in the absence or presence of peptides, and incubated 
at 37 °C for appropriate ime periods. For inhibition of the ICAM-2 peptide 
Pl-induced cell aggregation, cells were preincubated with different mono- 
clonal antibodies or inhibitors for 15 min at room temperature b fore being 
treated with the peptide. For quantitative measurement of cell aggregation, 
the free cells of four randomly chosen areas (2.5 mm 2) per well were 
counted. The amount of aggregated cells was expressed as: percent aggrega- 
tion = 100 × [1-(number of free cells)/(total number of cells)]. 
Flow Cytometry Studies 
THP-I and U937 cells were washed and resuspended in PBS, and treated 
with preimmune rabbit immunoglobulin to block the Fc receptors on the 
cells. Aliquots of 100 ttl of cell suspensions (106 cells) were incubated with 
25/~g/ml of different mAbs for 30 min at 0°C. The cells were washed and 
incubated with FITC-conjugated rabbit-anti-mouse F(ab')2 (Dako, Copen- 
hagen, Denmark) for 30 rain on ice. After washing, the cells were fixed with 
1% paraformaldebyde in PBS, and 5 x 103 cells were analyzed immedi- 
ately with a Becton-Dickinson (Immunocytometry System, San Jose, CA) 
FACScan flow cytometer. 
Binding of THP-I Cells to Fibrinogen or iC3b Coated 
on Plastic 
96-well microtiter plates were coated with purified fibrinogen (30 #g/ml in 
PBS), iC3b (2 #g/ml in PBS), or C3b (2 ~g/ml in PBS) for 16 h at 4°C. 
At the end of incubation, the wells were blocked with 1% BSA in PBS for 
2 h at room temperature. 100-/zl aliquots of ADP or ICAM-2 peptide- 
stimulated THP-1 cells at 2 x 106/ml in RPMI 1640 medium supple- 
mented with 40 mM Hepes, 2 mM MgCI2, 2 mM CaCI2 were added to 
each well, and incubated for 30 min at room temperature. For blocking ex- 
periments, the peptide-stimulated c lls were pretreated with different mAbs 
for 10 rain at 22°C before being added to fibrinogen, iC3b-, or C3b-coated 
wells. Nonadherent cells were removed by three washes with the binding 
medium. The binding was quantitated by scoring the number of attached 
cells with 200× magnification of four randomly chosen fields from each 
well. 
Results 
Binding of lCAM-2 Peptide to CDllb/CD18 
The purified CDllb/CD18 and CDllc/CD18 preparations 
were checked by polyacrylamide g l electrophoresis in the 
presence of SDS. The preparations contained the expected 
CD1 lb, CD1 lc, and CD18 polypeptides, and no major impu- 
rities were observed (Fig. 1 A, a and b). Most of the purified 
integrins was in functional intact heterodimeric forms as ex- 
amined by running the preparations through the affinity 
columns once again, and checking the eluates bySDS-PAGE 
(Fig. 1 A, c and d). The ~25I-labeled ICAM-2 peptide P1 
bound to purified CD1 lb/CD18 coated on plastic, while little 
binding was observed to the purified CDllc/CD18 or BSA. 
The binding of J25I-labeled P1 to CDllb/CD18 was specifi- 
cally and almost otally inhibited by unlabeled P1 (Fig. 2 A). 
The control peptide P8 had no effect. The purified CD1 lc/ 
CD18 was in active form as shown by the fact that Eahy926 
cells bound to CDllc/CD18 coated on plastic, and the bind- 
ing was blocked by the CDllc antibody 3.9 (Fig. 2 B). The 
binding of t25I-labeled P1 to CDllb/CD18 was saturable 
(Fig. 3 A), and efficiently blocked by the anti-CD1 lb mAb 
Figure 1. Polyacrylamide gels of purified CDllb/CD18, CDI lc /  
CD18, fibrinogen, and iC3b. Purified CDl lb/CD18 (A a) and 
CD1 lc/CD18 (,4 b) were run on 8 % poyacrylamide gels in the pres- 
ence of SDS and stained with Coomassie blue. The heterodimeric 
forms of CD1 lb/CD18 (A c) and CD1 lc/CD18 (,4 d) were checked 
on 6% polyacrylamide gels. The positions of  the molecular weight 
markers are indicated to the right. B shows the purified fibrinogen 
and iC3b preparations. 
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Figure 2. Binding of t2SI-labeled P1 peptide to purified CDllb/ 
CD18 and CDllc/CD18, and binding of Eahy926 cells to CDIlc/ 
CD18. 12 pmol of n25I-labeled P1 was incubated in CDIlb/CD18 
or CD1 lc/CD18-coated wells in the absence or presence of 100/~M 
of nonradioactive P1or P8 peptides (A). 50 #g/ml of mAb 3.9 and 
control antibody MIgG was used to block the adhesion of Eahy926 
cells to CD1 lc/CDI 8 coated on plastic (B). The standard eviations 
are shown. The inhibitory effects of competing peptide P1 and mAb 
3.9 were significant. *** p < 0.001. 
OKM10, but not by the other CDllb antibodies OKM1, 
LM2/1, or 60.1, nor by the anti-CD18 mAb 7E4. The soluble 
CDllb/CD18 ligands fibrinogen, iC3b, and factor X were 
not inhibitory (Fig. 3 B). 
ICAM-2 Peptide Pl-induced 
CDllb/CD18-ICAM-l-dependent 
Cell Aggregation 
The kinetics of THP-1 and U937 cell aggregation i duced by 
the peptide P1 was similar (Fig. 4 A and Fig. 5 A). After 
0.5-1 h incubation with P1, the cells clearly aggregated as 
compared to cells treated with the control peptide P8, or 
cells left without any treatment. Maximal aggregation was 
observed after 3-4 h incubation, and the cells remained in 
clusters during the experiments. Peptide P1 induced cell 
aggregation in a concentration-dependent manner, and a 
50% aggregation was obtained with '~30 or 40/xM of P1 for 
THP-1 or U937 cells, respectively (Fig. 4 B and Fig. 5 B). 
The expression of leukocyte adhesion molecules on THP-1 
220 
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Figure 3. Saturation curve of the binding of ~25I-labeled P1 to 
purified CDI lb/CDl 8, and inhibition of the interaction with mono- 
clonal antibodies. 12 pmol of ~25I-P1 was incubated in CDllb/ 
CD18-coated wells in the presence of increasing amounts of unla- 
beled PI (A), or 50/zg/ml of monoclonal ntibodies to CD18 (7E4), 
CDllb (OKMI, OKMI0, LM2/I, and 60.1), and control antibody 
MIgG1, or 50/~g/ml of fibrinogen (Fg), iC3b, or factor X (FX) (B). 
The inhibitory effect of mAb OKMI0 was significant. ** p < 0.01. 
and U937 cells was studied by flow cytometry. CD18, 
CDllb, CDllc, ICAM-1, ICAM-2, and ICAM-3 were well 
expressed on both THP-1 and U937 cells, while little expres- 
sion of CDlla was found (Fig. 6). Monoclonal antibodies 
against CD18 and ICAM-1 efficiently blocked the homotypic 
adhesion of both THP-1 and U937 cells, whereas the anti- 
CDllb antibodies OKM1, LM2/1, and 60.1 (for U937) 
blocked to a smaller, but significant extent (Fig. 4 C and Fig. 
5 C). The CDllb antibody OKM10 and antibodies against 
CDlla, CDllc, ICAM-2, and ICAM-3 did not inhibit the 
aggregation. 
Temperature, Energy, Microfilament, and Divalent 
Cation Requirements forICAM-2 Peptide Pl-induced 
Cell Aggregation 
No Pl-stimulated homotypic adhesion of THP-1 and U937 
cells was detected at 4°C (Fig. 7, A and B). The aggregation 
was partially blocked by NAN3, but completely inhibited by 
using NaN3 in combination with 2-deoxy-o-glucose. Cyto- 
chalasin B, which prevents the formation of microfilaments, 
partially inhibited the aggregation, and EDTA blocked effi- 
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Figure 4. Peptide Pl-induced THP-I cell aggregation. (A) THP-1 
cells were treated with 40 #M of peptides P1 (e) or P8 (e), or left 
without any treatment (A), for indicated time periods. (B) The 
cells were treated with different amounts of P1 or P8. (C) 50 tLg/ml 
of mAbs 7E4 (CD18), TS1/22 (CDlla), OKM1 (CDIlb), OKM10 
(CDllb), LM2/1 (CDIlb), 60.1 (CDllb), 3.9 (CDllc), LB-2 
(ICAM-1), B-T1 (ICAM-2), CG106 (ICAM-3), and MIgG1 control 
atnibody were used in the blocking assays. The cell aggregations 
in B and Cwere evaluated after a 3-h incubation. The standard devi- 
ations and statistic significances are shown. 
ciently. Treatment of cells with dibutyryl cAMP, a cell- 
permeable cAMP analogue, slightly blocked the homotypic 
cell adhesion of THP-1 cells, but had no effect on U937 cells. 
ICAM-2 Peptide Pl-induced Adhesion of THP-1 Cells 
to Fibrinogen 
The purified fibrinogen was checked by polyacrylamide g l 
electrophoresis in the presence of SDS and found to be es- 
sentially pure (Fig. 1 B). THP-1 cells stimulated with the 
peptide P1 bound much more efficiently to fibrinogen coated 
on plastic (Fig. 8, A, B, and C a) than cells pretreated with 
the control peptide P8 (Fig. 8, A, B, and Cb) or cells left with- 
out any treatment (Fig. 8, A and B). ADP treatment also in- 
creased the binding of THP-1 cells to fibrinogen, but to a 
smaller extent (Fig. 8 A). 1 #M of P1 induced a substantial 
binding of THP-1 cells to fibrinogen, and the adhesion in- 
creased with increasing amounts of the P1 peptide (Fig. 8 B). 
The Pl-induced adhesion of THP-1 cells to fibrinogen was 
efficiently blocked by monoclonai ntibodies to CD18 (7E4) 
and CD1 lb (OKM10), partially blocked by the CD1 lc anti- 
bodies 3.9 and 2El, and totally inhibited when antibodies 
OKM10 and 3.9 were used together (Fig. 9). The epitopes 
on CDllb/CD18 recognized by the monoclonal antibodies 
OKM1, OKM10, LM2/1, and 60.1 were expressed at similar 
levels on THP-1 cells (Fig. 6, data not shown). However, with 
the exception of OKM10, the other CD1 lb antibodies OKM1, 
LM2/1, and 60.1 did not block the binding. Another integrin 
receptor for fibrinogen, e¢4~3, is also expressed on THP-1 
cells (data not shown), but the antibody LM609 reacting 
with this receptor was not inhibitory. The antibody to CD1 la 
(TS1/22), and the control antibody had no effect. EDTA abol- 
ished the adhesion completely. 
ICAM-2 Peptide Pl-induced Adhesion of THP-1 Cells 
to Complement Fragment iC3b 
The purified iC3b preparation was checked by polyacryl- 
amide gel electrophoresis in the presence of SDS. It con- 
tained the ~ chain and the typical ot chain fragments, and no 
major impurities were observed (Fig. 1 B). Nonstimulated 
THP-1 cells bound to iC3b coated on plastic, but ADP and 
P1 peptide increased the binding to a small but significant ex- 
tent, whereas the control peptide P8 had no effect (Fig. 10 
A). The binding was efficiently inhibited by mAb 7E4, par- 
tially by OKM10 and 3.9, and an additive ffect was observed 
when OKM10 and 3.9 were used together (Fig. 10 B). Anti- 
bodies TS1/22, OKM1, LM2/1, and 60.1 were not inhibitory, 
whereas EDTA blocked the interaction. Little binding oc- 
curred to C3b. 
Discussion 
CDllb/CD18 is the predominant myeloid cell integrin 
(Springer, 1990; Arnaout, 1990; Patarroyo et al., 1990). It 
is involved in cell-cell interactions, and has been shown to 
bind to the third immunoglobulin domain of ICAM-1 (Dia- 
mond et al., 1991). Furthermore, it binds to several soluble 
proteins like fibrinogen (Wright et al., 1988; Altieri et al., 
1988), iC3b (Belier et al., 1982; Wright et al., 1983), and 
factor X (Altieri and Edgington, 1988a), and to various 
complex carbohydrates (Ross et ai., 1985; Wright and Jong, 
1986). The binding specificity of CDllc/CD18, which is 
mainly found on macrophages, is less understood, but it 
binds to fibrinogen (Loike et al., 1991; Postigo et al., 1991), 
iC3b (Micklem et al., 1985; Myones et al., 1988), and a 
counter-receptor on the surface of endothelial cells (Stacker 
and Springer, 1991), which was confirmed in the present 
work. 
Obviously, it is important to define the leukocyte integrin 
ligands in detail, determine the binding sites, and establish 
the mode of activation. ICAM-2 is a relatively simple inte- 
grin ligand, and therefore we thought that it should be an ex- 
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Figure 5. Peptide Pl-induced U937 cell aggregation. (A) U937 cells 
were treated with 40 #M of peptides P1 (-) or P8 (e), or left with- 
out any treatment (A), for indicated time periods. (B) The cells 
were treated with different amounts of P1 or PS. (C) The antibody 
blocking assays were performed as shown in Fig. 4. The aggregations 
of cells in B and C were evaluated after a 4-h incubation. The stan- 
dard deviations are shown. * p < 0.05; ** p < 0.01; *** p < 0.001. 
cellent model for detailed studies on integrin-ligand interac- 
tions. 
We previously showed that the 22-amino acid residue pep- 
tide P1, derived from the first immunoglobulin domain of 
ICAM-2, specifically binds to CDlla/CD18 (Li et al., 
1993b). However, we did not find any CDlla antibody that 
blocked the interaction. The P1 peptide inhibits the binding 
of endothelial cells to purified CD1 la/CD18, and the binding 
of lymphoblastoid cells to endothelial cells (Li et al., 
1993b). In the present study, we show that the same peptide 
also specifically binds to purified CDllb/CD18, but not to 
THP-1 U937 
. | O" "'"I"~I" ""+i'll2" " ' i r~ . "' ' i '~N 
A 
CDl la  
CD11b i 
CD11c 3i i 
ICAM-I o! 
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. ~i++ '"i73c ' i on  ' i i~+ " i~ ~ 
Figure 6. Expression of CDll/CD18 integrins and ICAMs on the 
monocytic ell lines THP-1 and U937. The monoclonal ntibodies 
7E4 (CD18), TS1/22 (CD1 la), OKMI0 (CDI lb), 3.9 (CD1 lc), LB-2 
(ICAM-I), B-T1 (ICAM-2), CG106 (ICAM-3) (dark lines), and 
mouse IgG1 (control) (gray lines) were used. The expression of the 
epitopes recognized by the CD1 lb antibodies OKM1, LM2/I, and 
60.1 was similar to that of the OKMI0 epitope (data not shown). 
CDllc/CD18. The anti-CDllb mAb, OKM10, which recog- 
nizes a discontinuous epitope that requires the presence of 
both the NH2-terminal and divalent cation-binding regions 
(Diamond et al., 1993), efficiently blocked this interaction. 
The results suggest hat the epitope recognized by mAb 
OKM10 on the c~ chain is in the vicinity of the binding site 
for the P1 peptide. However, the soluble ligands for CD1 lb/ 
CD18 fibrinogen, iC3b, and factor X, were not able to inter- 
fere with this interaction, indicating that different regions on 
CD1 lb/CD18 are involved in binding of P1 and these ligands. 
The binding of the ICAM-2 derived peptide to CD1 lb/CD18 
raises the interesting possibility that ICAM-2 could bind 
to this integrin. It has been shown that there exists a sec- 
ond CD1 lb/CD18 ligand on vascular endothelium, besides 
ICAM-1 (Carlos and Harlan, 1994). Our preliminary results 
indicate that ICAM-2 binds to CDllb/CD18 (Xie, J., R. Li, 
P. Kotou, C. Kantor, C. Vermot-Desroches, J. Wijdenes, 
M. A. Arnaout, P. Natamo, and C. G. Gahmberg, manu- 
script in preparation). 
The peptide P1 is relatively hydrophobic, and most part of 
it is probably buried in the first domain of ICAM-2, except 
that both of its NILE- and COOH-terminais seem to be ex- 
posed (Li et al., 1993b). It is essential that the peptide is in 
reduced form. We have found that when preserved without 
the presence of reducing agents, the peptide was easily oxi- 
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Figure 7. Inhibition of peptide Pl-induced THP-1 and U-937 cell 
aggregations. THP-1 (A) and U937 (B) cells were kept at 4°C or 
pretreated with 0.2% of NAN3, 0.2% NaN3 and 50 mM 2-deoxy- 
D-glucose, 20 #M cytochalasin B,2 mM dibutyryl cAMP or 5 mM 
EDTA for 15 min at room temperature, before the addition of 40 
/~M of P1 peptide. The aggregations were determined after 3-h or 
4-h incubations for THP-1 and U937, respectively, at 37°C, with the 
exception of the assay marked 4°C. 
dized and lost activity. On the other hand, alkylated peptide 
did not work either (data not shown). Therefore, the two cys- 
teines in the peptide seem to be essential for its activity. 
Recently, we found that the ICAM-2 peptide strongly in- 
duces blood T cell aggregation, which s mainly mediated by 
CDlla/CD18-ICAM-1 interaction, and an increase in the 
binding and cytotoxicity of natural killer cells (Li et al., 
1993a). Here we show that the stimulatory effect is not re- 
stricted to T lymphocytes and natural killer cells. My- 
elomonocytic THP-1 and U937 cells became aggregated af- 
ter treatment with the P1 peptide. Blood neutrophils were 
also strongly aggregated by P1 stimulation (data not shown). 
Unlike T lymphocytes, on which CDlla/CD18 is the main 
leukocyte integrin expressed, CDllb/CD18 and CDllc/CD18 
are well expressed on THP-1 and U937 cells, while there is 
little expression of CDlla/CD18. The THP-1 and U937 cell 
aggregations were efficiently blocked by CD18 and ICAM-1 
antibodies. The CDllb antibodies OKM1, LM2/1, and 60.1 
(for U937) blocked to a smaller, but significant extent, while 
CD1 la and CD1 lc antibodies had no effect. These results in- 
Figure 8. Peptide Pl-induced adhesion of THP-I cells to fibrinogen 
coated on plastic. (,4) THP-1 cells were preincubated with 40 #M 
of peptides P1 or P8 for 2 h at 37°C, washed, and resuspended by 
pipetting, before being added to fibrinogen or BSA-coated wells. 10 
#M of ADP was added at the same time when the cell suspension 
was added tothe wells. (B) THP-1 cells were stimulated with differ- 
ent concentrations f PI (u) or P8 (o), or left without any treat- 
ment (A), before being added to fibrinogen-coated wells. (C) 
Binding of peptide P1 (C a) or P8 (C b)-stimulated THP-I cells to 
immobilized fibrinogen. The photomicrographs were tak n after 
the nonadherent cells had been removed by washing three times. A 
200x magnifcation was used. The bar indicates 50/~m. 
dicate that CDllb/CD18 becomes activated, and mediates 
the cell aggregation by interacting with ICAM-1. Since the 
CDllb antibody OKM10, which blocked the binding of P1 
peptide to purified CDllb/CD18, did not inhibit the THP-1 
and U937 cell aggregation, it is probable that CDIlb/CD18 
is activated by signals resulting from the interaction of P1 
with the small amount of CDlla/CD18 expressed on the 
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Figure 9. Inhibition of peptide Pl-induced adhesion of THP-I ceils 
to immobilized fibrinogen by monoclonal antibodies and EDTA. 
Aliquots of Pl-stimulated THP-1 cells were separately pretreated 
with 50 /.tg/ml of mAbs against CD18 (7E4), CDlla (TS1/22), 
CDIlb (OKM1, OKM10, LM2/1, and 60.1), CDllc (3.9, 2El), 
avfl3 (LM609) and control MIgG1, before being added to fibrino- 
gen-coated wells. 5 mM EDTA was used. The effect of P1 is sig- 
nificant as indicated. 
cells. Alternatively, during the incubation of the cells at 
37°C, the OKM10-engaged CDllb/CD18 molecules are no 
longer available on the cell surface, because of the rapid in- 
ternalization of occupied CD1 lb/CD18 (Rab et al., 1993). It 
has been shown that translocation fneutrophil CD1 lb/CD18 
complex to the cell surface can be induced at 37°C (Todd et 
al., 1984). We think that a minor possibility could be that 
these OKM10-free CD1 lb/CD18 derived from the intracellu- 
lar pool bound P1 and became activated. 
Peptide Pl-induced homotypic adhesion of THP-1 and 
U937 cells does not happen at 4°C, and requires energy, in- 
tact microfilaments, and divalent cations. However, cyto- 
chalasin B, which prevents the formation of microfilaments, 
could not totally block the aggregation; and CD18 antibody 
7E4 was not able to completely inhibit the aggregation ei- 
ther. These findings suggested that besides f12 integrins, 
some other integrins or adhesion systems were also acti- 
vated. 
We previously reported that cross-linking of CD1 lb/CDI 8 
on neutrophils with monoclonal antibodies causes a rise in 
cytosolic free Ca 2+, which is functionally coupled to a tran- 
sient activation state of CDllb/CD18 (Altieri et al., 1992). 
In addition, engagement of the divalent ion binding site(s) on 
CD1 lb/CD18 induces the expression of activation-dependent 
neoantigenic epitopes on CDllb/CD18 and leukocyte adhe- 
sion (Altieri, 1991). Furthermore, binding of eosinophils 
to endothelial cells causes a considerable upregulation of 
CDllb and an increased capacity to generate an oxidative 
burst (Walker et al., 1993). It is possible that binding of P1 
to CDllb/CD18 has a similar effect as CDllb-specific ac- 
tivating antibodies. The complexity of integrin-activating an- 
tibodies is illustrated by the opposite ffects of CD1 la and 
CD18 antibodies on T cell activation (van Noesel et al., 
1988). In the presence of CD18 antibodies, CD1 la antibodies 
increased T cell proliferation, whereas CD18 antibodies 
were inhibitory. These findings indicate that integrin-ligand 
Figure 10. Peptide Pl-induced adhesion of THP-1 cells to iC3b or 
C3b coated on plastic. (A) THP-1 cells were preincubated with 40 
/xM of peptides P1 or P8 for 2 h at 37°C, washed, resuspended by 
pipetting, and added to iC3b- or C3b-coated wells. 10/xM of ADP 
was added at the same time when the cell suspension was added to 
the wells. (B) Aliquots of Pl-stimulated THP-1 cells were sepa- 
rately pretreated with 50 /~g/ml of mAbs against CDI8 (7E4), 
CDI la (TS1/22), CD1 lb (OKM1, OKM10, LM2/I, and 60.1), CD1 lc 
(3.9), and control MIgGI, before being added to iC3b-coated wells. 
5 mM EDTA was used. 
binding may have different effects on integrin functions de- 
pending on the site of interaction. 
Although several stimuli such as phorbol esters, the pep- 
tide formyl-methionyl-leucyl-phenylalanine and complement 
fragment C5a, can increase the cell surface expression of 
CDllb/CD18 (Lo et al., 1989; Detmers et al., 1990; Dia- 
mond and Springer, 1993), no detectable increase in CD1 lb/ 
CD18 expression on granulocytes and THP-I cells was ob- 
served after treatment with P1 (data not shown). Phorbol es- 
ter or ADP-induced high avidity state of CDllb/CD18 is 
characterized by the formation of activation-dependent neo- 
antigenic epitopes recognized by the ct chain antibodies 
CBRM1/5 (Diamond and Springer, 1993) or 7E3 (Altieri and 
Edgington, 1988b). However, the P1 peptide-stimulated 
functional modulation of CD1 lb/CD18 was not accompanied 
by an increased expression of these epitopes (data not 
shown). Recent work has shown by using CD18 antibodies, 
that the peptide P1 was able to induce the aggregation of the 
/32 integrins in the plane of cell membrane on natural killer 
cells (Somersalo et al., 1995), which is supposed to be 
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tightly correlated with high ligand-binding capacity of 
CDllb/CD18 (Detmers et al., 1987). 
The adhesion of THP-1 cells to fibrinogen and iC3b, was 
increased by stimulating the cells with peptide P1. The inter- 
actions were efficiently blocked by CD18, CD1 lb, and CD1 lc 
antibodies, and an additive ffect was observed when CD1 lb 
and CD1 lc antibodies were used together. The Pl-stimulated 
adhesion of THP-1 cells to immobilized fibrinogen and iC3b 
was blocked by the antibody OKM10, which was found pre- 
viously to be able to block the interactions between leuko- 
cytes and immobilized fibrinogen and iC3b (Wright et al., 
1983, 1988; Anderson et al., 1986). On the other hand, 
some reports have shown that OKM1, rather than OKM10, 
inhibits the interaction between the leukocytes and soluble 
fibrinogen (Altieri et al., 1988, 1990). It has been found that 
conformational changes occur in fibrinogen when the protein 
is adsorbed onto a plastic surface (Ugarova et al., 1993). 
This could be the reason for the fact that soluble fibrinogen 
did not inhibit the interaction between P1 and CDllb/CD18, 
in which the OKM10 epitope was involved. The background 
binding of resting THP-1 cells to iC3b coated on plastic was 
quite high, because iC3b constitutes a ligand for nonacti- 
vated CDllb/CD18 (Ross and Vetvicka, 1993). 
Taken together, our results are compatible with a model 
in which the ICAM-2-derived peptide PI binds to the leuko- 
cyte integrins CDlla/CD18 (Li et al., 1993b) and CDllb/ 
CD18, but not to CDllc/CD18. These interactions induce 
high avidity states of CDlla/CD18 on T lymphocytes (Li et 
al., 1993a), and CDllb/CD18 and CDllc/CD18 on mono- 
cytic cells for their ligands (Fig. 11). Evidently, the activation 
of CDllb/CD18 and CDllc/CD18 involves both outside-in 
and inside-out signals, but it is not clear yet whether the sig- 
nals come from the interaction of P1 peptide with CDlla/ 
CD18, or with CDllb/CD18, or with both. The detailed 
mechanisms involved in the signaling remain poorly under- 
stood. 
We tested the ability of peptide P1 to induce the binding 
of CDllb/CD18 transfected CHO cells to fibrinogen. The 
CDllb and CD18 are in the expression vector H3M (Dana 
et al., 1991), and was obtained from Dr. M. A. Arnaout. Ap- 
proximately 20-30% of the transfected cells expressed 
CDllb/CD18 as determined by FACScan analysis. The 
CDllb/CD18 transfected cells bound to fibrinogen, but no 
additional activation by P1 was observed (data not shown). 
Phorbol esters were not either capable of activating the trans- 
fected cells. These findings how that he CD1 lb/CD18 is ac- 
tive in the transfected cells, but further activation isdifficult 
to achieve. Evidently, CHO cells lack the activation system 
found in leukocytes. 
Recent studies have provided evidence of how fibrinogen 
participates in inflammatory responses and host defense. 
Fibrinogen is involved in the regulation of leukocyte adhe- 
sion to vascular endothelium by interacting with both 
CDllb/CD18 on leukocytes and ICAM-1 on endothelium 
(Altieri et al., 1993; Languino et al., 1993). The finding that 
P1 stimulates the binding of leukocytes to fibrinogen raises 
the intriguing possibility that ICAM-2, which is constitu- 
tively expressed on most endothelia (Nortamo et al., 1991a; 
de Fougerolles et al., 1991), could have an important regula- 
tory role in leukocyte binding during physiological condi- 
tions. 
Besides the proposed triggering role for ICAM-2 peptide 
Figure 11. Hypothetical model to explain the ability of the ICAM- 
2-derived peptide P1 to regulate the avidity of leukocyte integrins. 
Peptide P1 binds to CDlla/CD18 and CDllb/CD18, but not o 
CDllc/CD18. The binding induces outside-in and inside-out sig- 
nals, by which CDlla/CD18 (Li et al., 1993a), CDllb/CD18, and 
CDllc/CDI8 are activated to bind to their ligands. 
P1 in ligand binding to integrin, it is obvious that his peptide 
also contributes to the adhesive interaction itself. This is 
based on the capacity of P1 to bind to purified CD1 la/CD18 
and CDllb/CD18, as well as the capacity of this peptide to 
inhibit the adhesion of endothelial cells to purified CD1 la/ 
CD18. Furthermore, it partially blocks the binding of B 
lymphoblastoid cells to endothelial cells (Li et al., 1993b). 
The ability of P1, on one hand, to inhibit the binding of 
ICAM-2 containing nonleukocytic cells to CD1 la/CD18, but 
on the other hand, to activate leukocyte binding, is incom- 
pletely understood. The main reason may be that as shown 
here, the three CDll/CD18 cellular integrins become acti- 
vated by P1, and they bind to several ligands at different bind- 
ing sites. Therefore, blocking of activated cell-bound inte- 
grins is more difficult han interference with the binding of 
single purified integrin to its ligands. 
An explanation for the high avidity ligand binding trig- 
gered by peptide P1 could be that additional ligand-binding 
sites are generated in the integrin, as proposed for the activa- 
tion of the platelet integrin gplIb/IIIa by arginine-glycine- 
aspartic acid (RGD)-containing peptides (Ruoslahti and 
Pierschbacher, 1986, 1987; Du et al., 1991). However, un- 
like the RGD-containing peptide-induced high affinity state 
of gplIb/IIIa, which appears to be due to a direct conforma- 
tional change in the receptor itself (Duet al., 1991), the P1- 
induced activation of B2 integrins eems to involve signal 
transduction events (Li et al., 1993a), although a direct effect 
on CDll/CD18 integrins cannot be excluded. 
Our results how that the high avidity state of leukocyte 
integrins for different ligands can be induced by interaction 
between the integrins and the ICAM-2-derived P1 peptide. 
This indicates the possibility of induction of active forms of 
leukocyte integrins through interaction with agonistic 
ligands. Such regulatory reagents could be useful in ther- 
apeutical maneuvers in the future. 
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Li et al. ICAM-2 Peptide Activates Leukocyte lntegrins 1151 
 o
n
 N
ovem
ber 6, 2006 
w
w
w
.jcb.org
D
ow
nloaded from
 
for the CDlla antibody TS1/22, Dr. N. Hogg for the CDllc antibody 3.9, 
Dr. C. Vermot-Desroches for the ICAM-2 antibody B-T1, Dr. D. L. Sim- 
mons for the ICAM-3 antibody CG106,, Dr. Jari Yl~inne for the avfl3 anti- 
body LM609 and purified fibrinogen, and Dr. M. A. Arnaout for the CD1 lb 
and CD18 containing expression vectors. 
This study was supported by the Academy of Finland, the Finnish Cancer 
Society, the Sigrid Jus61ius Foundation, University of Helsinki, the Magnus 
Ehrnroorth Foundation, the Centre for International Mobility (CIMO) 
Foundation, and grants RO1 HL-43773 and HL-51372 from the National 
Institutes of Health. 
Received for publication 28 June 1994 and in revised form 26 January 1995. 
References 
AItieri, D. C. 1991. Occupancy of CD 11 b/C D 18 (Mac- 1 ) divalent ion binding 
site(s) induces leukocyte adhesion. J  lmmunol. 147:1891-1898. 
Altieri, D. C., and T. S. Edgington. 1988a. The saturable high affinity associa- 
tion of factor X to ADP-stimulated monocytes defines a novel function of 
the Mac-1 receptor. J Biol. Chem. 263:7007-7015. 
Altieri, D. C., and T. S. Edgington. 1988b. A monoclonal ntibody reacting 
with distinct adhesion molecules defines a transition in the functional state 
of the receptor CDI Ib/CDI8 (Mac-i). J. lmmunol. 141:2656-2660. 
Altieri, D. C., R. Bader, P. M. Mannucci, and T. S. Edgington. 1988. Oligo- 
specificity of the cellular adhesion receptor Mac-1 encompasses an inducible 
recognition specificity for fibrinogen. J Cell Biol. 107:1893-1900. 
Altieri, D. C., F. R. Agbanyo, J. Plescia, M. H. Ginsberg, T. S. Edgington, 
and E. F. Plow. 1990. A unique recognition site mediates the interaction of 
fibrinogen with the leukocyte integrin Mac-1 (CD 11 b/CD 18), J. Biol. Chem. 
265:12119-12122. 
Altieri, D. C., J. Plescia, and E. F. Plow. 1993. The structural motif glycine 
190-valine 202 of the fibrinogen gamma chain interacts with CDI Ib/CDI8 
integrin (ot~2, Mac-l) and promotes leukocyte adhesion. J Biol. Chem. 
268:1847-1853. 
Altieri, D. C., S. J. Stamnes, and C. G. Gahmberg. 1992. Regulated Ca 2+ sig- 
naling through leukocyte CD1 Ib/CDI8 integrin. Biochem. J. 288:465-473. 
Anderson, D. C., L. J. Miller, F. C. Schmalstieg, R. Rothlein, and T. A. 
Springer. 1986. Contributions of the Mac-I glycoprotein family to ad- 
herence-dependent granulocyte functions: structure-function assessments 
employing subunit-specific monoclonal ntibodies. J. lmmunol. 137:15-27. 
Arnaout, M. A. 1990. Structure and function of the leukocyte adhesion mole- 
cules CDI 1/CDI8. Blood. 75:1037-1050. 
Bainton, D. F., L. J. Miller, T. K. Kishimoto, and T. A. Springer. 1987. Leu- 
kocyte adhesion receptors are stored in peroxidase-negative granules of hu- 
man neutrophils. J. Exp. Med. 166:1641-1653. 
Belier, D. I., T. A. Springer, and R. D. Schreiber. 1982. Anti-Mac-I selec- 
tively inhibits the mouse and human type three complement receptor. J Exp. 
Med. 156:1000-1009. 
Berendt, A. R., A. McDowall, A. G. Craig, P. A. Bates, M. J. E. Sternberg, 
K. Marsh, C. I. Newbold, and N. Hogg. 1992. The binding site on ICAM-I 
for plasmedium falciparum-infected erythrocytes overlaps, but is distinct 
from, the LFA-l-binding site. Cell. 68:71-81. 
Buyon, J. P., S. B. Abramson, M. R. Philips, S. G. Slades, G. D. Ross, G. 
Weissman, and R. J. Winchester. 1988. Dissociation between increased sur- 
face expression of gp165/95 and homutypic neutrophil aggregation. J. lm- 
munol. 140:3156-3160. 
Cabanas, C., and N. Hogg. 1993. Ligand intercellular dhesion molecule 1has 
a necessary role in activation of integrin lymphocyte function-associated 
molecule 1. Proc. Natl. Acad. Sci. USA. 90:5838-5842. 
Carlos, T. M., and J. M. Harlan. 1994. Leukocyte-endothelial adhesion mole- 
cules. Blood. 84:2068-2101. 
Cheresh, D. A., and R. C. Spiro. 1987. Biosynthetic and functional properties 
of an Arg-Gly-Asp-directed receptor involved in human melanoma cell at- 
tachment tovitronectin, fibrinogen, and von Willebrand factor. J. Biol. Chem. 
262:17703-17711. 
Clark, E. A., J. A. Ledbetter, R. C. Holly, P. A. Dinndorf, and G. Shu. 1986. 
Polypeptides on human B lymphocytes a sociated with cell activation. Hum. 
lmmunol. 16:100-113. 
Cordell, J. L., K. Pulford, H. Turley M. Jones K. Micklem, I. A. Doussis, 
X. Tyler, K. Mayne, K. C. Gatter, and D. Y. Mason. 1994. Cellular distri- 
bution of human leukocyte adhesion molecule ICAM-3. J. Clin. Pathol. 
47:143-147. 
Dan-de, N. K., K. Klussman, and A. Aruffo. 1992. Intercellular adhesion 
molecule-2, a second counter-receptor f r CD 11 a/CDI8 (leukocyte function- 
associated antigen-l), provides a costimulatory signal for T-cell receptor- 
initiated activation of human T cells. J. lmmunol. 148:665-671. 
Dana, N., D. M. Fathallah, and M. A. Arnaout. 1991. Expression of a soluble 
and functional form of the human /32 integrin CDI Ib/CDI8. Proc. Natl. 
Acad. Sci. USA. 88:3106-3110. 
Detmers, P. A., S. K. Lo, E. Olsen-Egbert, A. Walz, M. Baggiolini, and Z. A. 
Cohn. 1990. Neutrophil-activating protein 1/interleukin 8 stimulates the 
binding activity of the leukocyte adhesion receptor CD11b/CD18 on human 
neutrophils. J. Exp. Med. 171:1155-1162. 
Detmers, P. A., S. D. Wright, E. Olsen, B. Kimball, and Z. A. Cohn. 1987. 
Aggregation of complement receptors on human eatrophils in the absence 
of ligand. J. Cell Biol. 105:1137-1145. 
Diamond, M. S., and T. S. Springer. 1993. A subpopulation of Mac-I 
(CDIlb/CDI8) molecules mediates neutmphil adhesion to ICAM-1 and 
fibrinogen. J Cell Biol. 120:545-556. 
Diamond M. S., D. E. Stannton, S. D. Marlin, and T. A. Springer. 1991. Bind- 
ing of the integrin Mac-I (CD11b/CD18) to the third immunoglobulin-like 
domain of ICAM-I (CD54) and its regulation by glycosylation. Cell. 
65:961-971. 
Diamond, M. S., J. Garcia-Aguilar, J. K. Bickford A. L. Corbi, and T. A. 
Springer. 1993. The I domain is a major recognition site on the leukocyte 
integrin Mac-I (CDI Ib/CDI8) for four distinct adhesion ligands. J. Cell 
Biol. 120:1031-1043. 
Dransfield, I., A.-M. Buckle, and N. Hogg. 1990. Early events of the immune 
response mediated by leukocyte integrins. Immunol. Rev. 114:29--44. 
Du, X., E. F. Plow, A. Frelinger III, T. O'Toole, J. C. Loftos, and M. H. Gins- 
berg. 1991. Ligands "activate" integrin cq~3 (platelet GPllb-llla). Cell. 
65:409-416. 
Dustin, M. L., and T. A. Springer. 1989. T-cell receptor cross-linking tran- 
siently stimulates adhesiveness through LFA-1. Nature (Lond.). 341: 
619-624. 
Fawcett, J., C. L. L. Holness, L. A. Needham, H. Turley, K. C. Gater, D. Y. 
Mason, and D. L. Simmons. 1992. Molecular cloning of ICAM-3, a third 
ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 
(Lurid.). 360:481-484. 
de Fougerolles, A. R., and T. A. Springer. 1992. Intercellular adhesion mole- 
cule 3, a third adhesion counter-receptor f r lymphocyte function-associated 
molecule 1 on resting lymphocytes. J. Exp. Med. 175:185-190. 
de FougeroUes, A. D., S. A. Stacker, R. Schwarting, and T. A. Springer. 1991. 
Characterization f ICAM-2 and evidence for a third counter-receptor f
LFA-I. J, Exp. Med. 174:253-267. 
Greenwood, F. C., W. M. Hunter, and J. S. Gloves. 1963. The preparation 
of t~q-labeled human growth hormone of high specific radioactivity. Bio- 
chem. J. 89:114-123. 
Hernhndez-Caselles, T., G. Rubio, M. R. Campanero, M. A. de Pozo, M. 
Muro, F. Shnchez-Madrid, and P. Aparicio. 1993. ICAM-3, the third LFA-1 
counter-receptor, is acostimulatory molecule for both resting and activated 
T lymphocytes. Fur. J. lmmunol. 23:2799-2806. 
Juan, M., R. Vilella, J. Mila, J. Yagiie, A. Miralles, K. S. Campbell, R. J. 
Friedrich, J. Cambier, J. Vives, A. R. de Fougerolles, et al. 1993. CDw50 
and ICAM-3: two names for the same molecule. Eur. J. lmmunol. 
23:1508-1512. 
Kansas, G. S., and T. F. Tedder. 1991. Transmembrane signals generated 
through MHC class II, CDI9, CD20, CD39, and CD40 antigens induce 
LFA-1-dependent and independent adhesion i  human B cells through atyro- 
sine kinase-dependent pa hway. J Immunol. 147:4094--4102. 
Koistinen, V., S. Wessberg, and J. Leikola. 1989. Common binding region of 
complement factors B, H and CRI on C3b revealed by monoclonal nti-C3d. 
Complement lnflamm. 6:270-280. 
Koopman, G., M. de Graaff, A. C. L. M. Huysmans, C. J. L. M. Meijer, and 
S. T. Pals. 1992. Induction of homotypic T cell adhesion by triggering of 
leukocyte function-associated antigen-lot (CDlla): differential effects on 
resting and activated T cells. Fur. J. Immunol. 22:1851-1856. 
Koopman, G., Y. van Kooyk, M. de Graaff, C. J. L. M. Meyer, C. G. Figdor, 
and S. T. Pals. 1990. Triggering of the CD44 antigen on T lymphocytes pro- 
motes T cell adhesion through the LFA-1 pathway. J. lmmunol. 145: 
3589-3593. 
van Kooyk, Y., P. van de Wiel-van Kemenade, P. Weder, T. W. Kuijpers, and 
C. G. Figdor. 1989. Enhancement of LFA-l-mediated cell adhesion by trig- 
gering through CD2 or CD3 on T lymphocytes. Nature (Lond.). 342: 
811-813. 
Laemndi, U. K. 1970. Cleavage of structural proteins during assembly of the 
head of bacteriophage T4. Nature (Lond.). 227:680-685. 
Landis, R. C., R. I. Bennett, and N. Hogg. 1993. A novel LFA-I activation 
epitope maps to the I domain. J. Cell Biol. 120:1519-1527. 
Languino, L. R., J. Plescia, A. Duperray, A. A. Brian, E. F. Plow, J. W. Gel- 
tosky, and D. C. Altieri. 1993. Fibrinogen mediates leukocyte adhesion to 
vascular endothelium through an ICAM-l-dependent pathway. Cell. 73: 
1423-1434. 
Li, R., P. Nortamo, C. Kantor, P. Kovanen, T. Timonen, and C. G. Gahmberg. 
1993a. A leukocyte integrin binding peptide from intercellular adhesion 
molecule-2 stimulates T cell adhesion and natural killer cell activity. J Biol. 
Chem. 268:21474-21477. 
Li, R., P. Nortamo L. Valmu, M. Tolvanen, C. Kantor, and C. G. Gahmberg. 
1993b. A peptide from ICAM-2 binds to the leukocyte integrin CDI la/ 
CDI8 and inhibits endothelial cell adhesion. J Biol. Chem. 268:17513- 
17518. 
Lo, S. K., P. A. Detmers, S. M. Levin, and S. D. Wright. 1989. Transient 
adhesion of neutrophils to endothelium. J. Exp. Med. 169:1779-1793. 
Loike, J. D., B. Sodeik, L. Cao, S. Leucona, J. I. Weitz, P. A. Detmers, S. D. 
Wright, and S. C. Silverstein. 1991. CDI lc/CDI8 on neutrophils recog- 
nizes a domain at the N terminus of the Aot chain of fibrinogen. Proc. Natl. 
Acad. Sci. USA. 88:1044-1048. 
The Journal of Cell Biology, Volume 129, 1995 1152 
 o
n
 N
ovem
ber 6, 2006 
w
w
w
.jcb.org
D
ow
nloaded from
 
M icklem, K. J., and R. B. Sim. 1985. Isolation of complement-fragment-iC3b- 
binding proteins by affinity chromatography. The identification of p150,95 
as an iC3b-binding protein. Biochem. J. 231:233-236. 
Miller, L. J., D. F. Bainton, N. Booregaard, and T. A. Springer. 1987. Stimu- 
lated mobilization of monocyte Mac-I and p150,95 adhesion proteins from 
an intraceUular vesicular compartment tothe cell surface. J. Clin. Invest. 
80:535-544. 
Miller, L. J., R. Schwarting, and T. A. Springer. 1986. Regulated expression 
of the Mac-l, LFA-I, p150,95 glycoprotein family during leukocyte 
differentiation. J. lmmunol. 137:2891-2900. 
Myones, B. L., J. G. Daizell, N. Hogg, and G. D. Ross. 1988. Neutrophil and 
monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling 
CR3. J. Clin. Invest. 82:640-651. 
van Noesel, C., F. Miedema, M. Brouwer, M. A. de Rie, L. A. Aarden, and 
R. A. W. van Lier. 1988. Regulatory properties of LFA-I ct and/~ chains 
in human T-lymphocyte activation. Nature (Lond.). 333:850-852. 
Nortamo, P., M. Patarroyo, C. Kantor, J. Suopanki, and C. G. Gahmberg. 1988. 
Immunological mapping of the human leukocyte adhesion glycoprotein 
GP90 (CDIS) by monoclonal ntibodies. Scand. J. lmmunol. 28:537-546. 
Nortamo, P., R. Li, R. Renkonen, T. Timonen, J. Prieto, M. Pataroyo, and 
C. G. Gahmberg. 1991a. The expression of human intercellular adhesion 
molecule-2 is refractory to inflammatory c tokines. Eur. J. lmmunol. 21: 
2629-2632. 
Nortamo P., R. Salcedo, T. Timonen, M. Patarroyo, and C. G. Gahmberg. 
1991b. A monoclonal ntibody to the human leukocyte adhesion molecule 
intercellular dhesion molecule-2. Cellular distribution and molecular char- 
acterization of the antigen. J. lmmunol. 146:2530-2535. 
Patarroyo, M., P. G. Beatty, J. W. Fabre, and C. G. Gahmberg. 1985. 
Identification of a cell surface protein complex mediating phorbol ester- 
induced adhesion (binding) among human mononuclear leukocytes. Scand. 
J. lmmunoL 22:171-182. 
Patarroyo, M., E. A. Clark, J. Prieto, C. Kantor, and C. G. Gahmberg. 1987. 
Identification ofa novel adhesion molecule in human leukocytes by monoclo- 
hal antibody LB-2. FEBS (Fed. Eur. Biochem. Soc.) Lett. 210:127-131. 
Patarroyo, M., J. Pricto, J. Rincon, T. Timonen, C. Lundberg, L. Lindbom, 
B./~sj6, and C. G. Gahmberg. 1990. Leukocyte-cell adhesion: amolecular 
process fundamental in leukocyte physiology, lmmunol. Rev. 114:67-108. 
Philips, M. R., J. P. Buyon, R. Winchester, G. Weissman, and S. B. Abram- 
son. 1988. Up regulation of the iC3b receptor (CR3) is neither necessary nor 
sufficient to promote neutrophil aggregation. J. Clin Invest. 82:495-501. 
Postigo, A. A., A. L. Corbi, F. S~inchez-Madrid, and M. O. de Land~uri. 
1991. Regulated expression and function of CD 11 clCDI 8 integrin on human 
B lymphocytes. Relation between attachment to fibrinogen and triggering of 
proliferation through CDI lc/CDI8. J. Exp. Med. 174:1313-1322. 
Rabb, H., M. Michishita, C. P. Sharma, D. Brown, and M. A. Arnaout. 1993. 
Cytoplasmic tails of human complement receptor type 3 (CR3, CDI lb/ 
CD 18) regulate ligand avidity and the internalization foccupied receptor. 
J. lmmunol. 151:990-1002. 
Ross, G. D., J. A. Cain, and P. J. Lachmann. 1985. Membrane complement 
receptor type 3 has leetin-like properties analogous to bovine conglntinin and 
functions as a receptor for zymosan and rabbit erythrocytes as well as a 
receptor for iC3b. J. Immunol. 134:3307-3315. 
Ross, G. D., and V. Vetvicka. 1993. CR3 (CDI Ib, CDIS): a phagocyte and 
NK cell membrane r ceptor with multiple ligand specificities and functions. 
Clin. Exp. lmmunol. 92:181-184. 
Rothlein, R., and T. A. Springer. 1986. The requirement for lymphocyte 
function-associated antigen 1 in homotypic leukocyte adhesion stimulated by 
phorbol ester. J. Exp. Med. 163:1132-1149. 
Rothlein, R., M. L. Dustin, S. D. Madin, and T. A. Springer. 1986. A human 
intercellular dhesion molecule (ICAM- 1) distinct from LFA- 1. J. Immunol. 
137:1270-1274. 
Ruoslahti, E., and M. D. Pierschbacher. 1987. New perspectives in cell adhe- 
sion: RGD and integrins. Science (Wash. DC). 238:491--497. 
Ruoslahti, E., and M. D. Pierschbacher. 1986. Arg-Gly-Asp: a versatile cell 
recognition signal. Cell. 44:517-518. 
S~inchez-Madrid, F., A. M. Krensky, C. F. Ware, E. Robbins, J. L. 
Strominger, S. F. Burakoff, and T. A. Springer. 1982. Three distinct anti- 
gens associated with human T-lymphocyte-mediated cytolysis: LFA-1, 
LFA-2, and LFA-3. Proc. Natl. Acad. Sci. USA. 79:7489-7493. 
van Seventer, G. A., Y. Shimizu, K. J. Horgan, and S. Shaw. 1990. The LFA-I 
ligand ICAM-I provides an important costimulatory signal for T cell 
receptor-mediated activation of resting T cell. J. lmmunol. 144:4579-4586. 
Somersalo, K., O. Carp6n, E. Saksela, C. G. Gahrnberg, P. Nortamo, and T. 
Timonen. 1995. Activation of NK cell migration by leukocyte integrin bind- 
ing peptide from ICAM-2. J. Biol. Chem. In press. 
Springer, T. A. 1990. Adhesion receptors of the immune system. Nature 
(Lond.). 346:425-434. 
Stacker, S. A., and T. A. Springer. 1991. Leukocyte integrin p150,95 
(CDI Ic/CDI8) functions as an adhesion molecule binding to a counter- 
receptor on simulated endothelium. J. ImmunoL 146:648-655. 
Staunton, D. E., M. L. Dustin, and T. A. Springer. 1989. Functional cloning 
of ICAM-2, a cell adhesion ligand for LFA-1 homologous toICAM-1. Na- 
ture (Lond.). 339:61-64. 
Staunton, D. E., M. L. Dustin, H. P. Erickson, and T. A. Springer. 1990. The 
arrangement of the immunoglobulin-like domains of ICAM-1 and the bind- 
ing sites for LFA-1 and rhinovirus. Cell. 61:243-254. 
Sundstr6m, C., and K. Nilsson. 1976. Establishment and characterization f 
a human histiocytic lymphoma cell line (U937). Int. J. Cancer. 17:565-577. 
Todd, R. F., M. A. Arnaout, R. E. Rosin, C. A. Crowley, W. A. Peters, and 
B. M. Babior. 1984 Subeellular localization of the large subunit of Mol (Mol 
alpha; formerly gp110), a surface glycoprotein associated with neutrophil 
adhesion. J Clin. Invest. 74:1280-1290. 
Tsuchiya, S., M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. 
Tada. 1980. Establishment and characterization f a human acute monocytic 
leukemia cell line (THP-I). Int. J. Cancer. 26:171-176. 
Ugarova, T. P., A. Z. Budzynski, S. J. Shattil, Z. M. Ruggeri, M. H. Gins- 
berg, and E. F. Plow. 1993. Conformational changes in fibrinogen elicited 
by its interaction with platelet membrane glycoprotein GPIIb-IIIa. J. Biol. 
Chem. 268:21080-21087. 
Vazeux, R., P. A. Hoffman, J. K. Tomita, E. S. Dickinson, R. L. Jasman, T. 
St. John, and W. M. Gallatin. 1992. Cloning and characterization f a new 
intercellular adhesion molecule ICAM-R. Nature (Lond.). 360:485-488. 
Vedder, N. B., and J. M. Harlan. 1988. Increased surface expression of 
Cd I I b/CD 18 (Mac- 1 ) is not required for stimulated neutrophil adherence to 
cultured endothelium. J. Clin. Invest. 81:676-682. 
Walker, C., S. Rihs, R. K. Braun, S. Betz, and P. L. B. Bruijnzeel. 1993. In- 
creased expression of CDI lb and functional changes in eosinophils after 
migration across endothelial cell monolayers. J. lmmunol. 150:4061-4071. 
Wallis, W. J., D. D. Hickstein, B. R. Schwartz, C. H. June, H. D. Ochs, P. G. 
Beatty, S. J. Klebanoff, and J. M. Harlan. 1986. Monocional antibody- 
defined functional epitopes on the adhesion-promoting glycoprotein complex 
(CDwlS) of human neutrnphils. Blood. 67:1007-1013. 
Wright, S. D., and M. T. C. Jong. 1986. Adhesion-promoting receptors on hu- 
man macrophages recognize Eschericia coil by binding to lipopolysaccha- 
ride. J. Exp. Med. 164:1876-1888. 
Wright, S. D., P. E. Rao, W. C. Van Voorhis, L. S. Craigmyle, K. Iida, M. A. 
Talle, E. F. Westberg, G. Goldstein, and S. C. Silverstein. 1983. Identifica- 
tion of the C3bi receptor of human monocytes and macrophages byusing 
monoclonal ntibodies. Proc. Natl. Acad. Sci. USA. 80:5699-5703. 
Wright, S. D., J. I. Weitz, A. J. Huang, S. M. Levin, S. C. Silverstein, and 
J. D. Loike. 1988. Complement receptor type 3 (CDI Ib/CDI8) of human 
polymorphonuclear leukocytes recognizes fibrinogen. Proc. Natl. Acad. Sci. 
USA. 85:7734-7738. 
Li et al. ICAM-2 Peptide Activates Leulagcyte lntegrins 1153 
 o
n
 N
ovem
ber 6, 2006 
w
w
w
.jcb.org
D
ow
nloaded from
 
